EU finalizes deal with Pfizer-BioNTech for 1.8 billion doses

The European Union’s executive arm has signed a third vaccine contract with Pfizer and BioNTech through 2023 for an additional 1.8 billion doses of their COVID-19 shots

BRUSSELS -- The European Union's executive arm on Thursday finalized a third vaccine contract with Pfizer and BioNTech through 2023 for an additional 1.8 billion doses of their COVID-19 shot. The European commission said the deal, which was agreed on behalf of all 27 EU countries earlier this month, will allow the buying of 900 million doses of the current shots and of a serum adapted to the virus' variants, with an option to purchase an extra 900 million shots. The signature of the agreement comes less than a week before a court hearing in Brussels pitting the Commission against the pharmaceutical company AstraZeneca, which is accused by the EU of failing to deliver the promised number of doses of its own vaccine. The Commission said that the deal with Pfizer-BioNTech stipulates that the production of doses must be based in the EU and that essential components are sourced from the region. “From the start of the supply in 2022, the delivery to the EU is guaranteed," the Commission said.